Peripheral blood-derived hematopoietic stem cells for leg gangrene

The aim of this study is to determine if intramuscular injection of autologous CD34+ cells is safe and effective in treating critical limb ischemia. Cell treatment was found to be safe and feasible and induced improvement in subjective and objective parameters of limb ischemia, which was sustained for up to 3 or 4 years.